WO2018101373A1 - ジアミン誘導体を含む口腔内崩壊錠 - Google Patents
ジアミン誘導体を含む口腔内崩壊錠 Download PDFInfo
- Publication number
- WO2018101373A1 WO2018101373A1 PCT/JP2017/042930 JP2017042930W WO2018101373A1 WO 2018101373 A1 WO2018101373 A1 WO 2018101373A1 JP 2017042930 W JP2017042930 W JP 2017042930W WO 2018101373 A1 WO2018101373 A1 WO 2018101373A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- orally disintegrating
- disintegrating tablet
- drug
- acid
- carmellose
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Definitions
- the present invention contains edoxaban, a pharmacologically acceptable salt thereof, or a solvate thereof, and rapidly disintegrates when included in the mouth or when placed in water, and is usually produced, transported, or used.
- the present invention relates to an orally disintegrating tablet having sufficient hardness and a method for producing the same.
- Tablets, capsules, granules, powders, etc. are known as dosage forms for oral solid preparations in the fields of pharmaceuticals and foods, but they are easier to take for elderly people, children and patients who have difficulty swallowing. Development of an orally disintegrating tablet that rapidly disintegrates when contained in the mouth or when placed in water is expected.
- Orally disintegrating tablets in addition to the property of rapidly disintegrating in the oral cavity, are required to have sufficient hardness to withstand physical impact during manufacture, transportation, and use, as with normal tablets. Yes.
- Patent Document 1 describes an orally disintegrating tablet containing a drug, crystalline cellulose having a bulk density of 0.23 g / cm 3 or less, sugar alcohol, and pregelatinized starch.
- this document does not describe an orally disintegrating tablet containing edoxaban and an organic acid.
- Patent Document 2 describes an invention related to a levofloxacin-containing tablet that is excellent in disintegration and suspension in water containing levofloxacin and hydroxypropylcellulose, but it is an oral cavity containing edoxaban, an organic acid, and hydroxypropylcellulose. There is no description about inwardly disintegrating tablets.
- Patent Document 3 includes (a) edoxaban, a pharmacologically acceptable salt thereof, or a solvate thereof, (b) one or more selected from sugar alcohols and water-swelling additives.
- a pharmaceutical composition with improved dissolution characterized by containing, and a tablet containing (c) a water-swellable additive in addition to (a) and (b) above, hypromellose, methylcellulose, ethylcellulose,
- An invention relating to a coated tablet coated with a coating agent containing at least one or more selected from hydroxypropyl cellulose and polyvinyl alcohol is described.
- the problem of this document is to obtain a pharmaceutical composition containing edoxaban, which has improved dissolution, and relates to an orally disintegrating tablet containing edoxaban and an organic acid and having both high disintegration property and dissolution property in water. There is no description.
- Patent Document 4 describes (a) edoxaban, a pharmacologically acceptable salt thereof, or a solvate thereof, and (b) a preparation with improved dissolution, which contains an organic acid.
- an orally disintegrating tablet having both sufficient disintegration property and sufficient hardness to withstand physical impact during production, transportation and use.
- the subject of the present invention contains edoxaban, a pharmacologically acceptable salt thereof, or a solvate thereof, and rapidly disintegrates when included in the mouth or when placed in water,
- An object of the present invention is to provide an orally disintegrating tablet having sufficient hardness for transportation and use and excellent storage stability.
- the present invention relates to (A) edoxaban, a pharmacologically acceptable salt thereof, or a solvate thereof, (B) an organic acid, and (C) 0.1 to 2.0% by weight based on the total weight of the tablet.
- An orally disintegrating tablet containing 1% of a water-soluble polymer and (D) a disintegrant and a method for producing the same are provided. That is, the present invention relates to the following (1) to (24).
- the disintegrant is one or more components selected from the group consisting of carmellose, crospovidone, carmellose calcium, croscarmellose sodium, corn starch, sodium starch glycolate, and pregelatinized starch ( The orally disintegrating tablet according to any one of 1) to (6).
- (12) (A) Edoxaban, a pharmacologically acceptable salt thereof, or a solvate thereof, (B) an organic acid, (C) 0.1 to 2.0% by weight of hydroxy based on the total weight of the tablet
- An orally disintegrating tablet comprising propylcellulose, (E) carmellose, (F) D-mannitol, (G) crystalline cellulose having a bulk density of 0.26 g / cm 3 or less, and (H) pregelatinized starch.
- the present invention contains edoxaban, its pharmacologically acceptable salt, or a solvate thereof, and has rapid disintegration and solubility when placed in the oral cavity or water, and has a good mouthfeel. It was possible to provide an orally disintegrating tablet having sufficient hardness in the process of normal production, transportation and use, and excellent storage stability.
- an orally disintegrating tablet is a compression-molded product that has rapid disintegration and solubility when contained in the mouth or in water. Specifically, it means a tablet that normally disintegrates in about 5 to 180 seconds, preferably 5 to 60 seconds, more preferably about 5 to 40 seconds in a disintegration test mainly by saliva in the oral cavity or a disintegration test by a device. .
- the orally disintegrating tablet of the present invention has sufficient hardness in the process of normal production, transportation and use.
- it is an orally disintegrating tablet having a hardness of usually 2 kg or more, preferably 3 kg or more, more preferably 5 kg or more.
- the orally disintegrating tablet of the present invention retains dissolution properties suitable for pharmaceutical products.
- it is an orally disintegrating tablet that normally exhibits an average dissolution rate of 80% or more, preferably 85% or more at 30 minutes.
- Edoxaban used in the present invention is the following formula (1)
- Compound 1 may be a solvate (including a hydrate), a pharmacologically acceptable salt, or a solvate thereof (including a hydrate).
- the pharmacologically acceptable salt or solvate thereof preferably has the following formula (1a)
- Edoxaban used in the present invention produces activated blood coagulation factor X (activated blood coagulation factorX or FXa) having an action of forming thrombus by generating thrombin from prothrombin and promoting fibrin formation in the blood coagulation cascade. By inhibiting selectively, reversibly and directly, a thrombus formation inhibitory action is expressed.
- Edoxaban used in the present invention has been shown to be effective in suppressing the onset of venous thromboembolism in patients undergoing orthopedic surgery of the lower extremities including total knee replacement, total hip replacement, and hip fracture surgery in clinical trials conducted in Japan and overseas. It is used to suppress the onset of ischemic stroke and systemic embolism in patients with valvular atrial fibrillation, and to treat and suppress recurrence of venous thromboembolism (deep vein thrombosis and pulmonary thromboembolism).
- Edoxaban contained in the orally disintegrating tablet of the present invention suppresses the onset of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation, and venous thromboembolism (deep vein thrombosis and pulmonary thromboembolism)
- adults are orally administered once a day at a dose of 30 mg (when body weight is 60 kg or less) or 60 mg (when body weight exceeds 60 kg) as edoxaban.
- the dose can be reduced to 30 mg once a day according to renal function and concomitant drugs.
- 30 mg of edoxaban is orally administered to an adult once a day.
- “acid” refers to a compound that exhibits acidity and can be added to a pharmaceutical product, and includes organic acids and inorganic acids.
- organic acid refers to an organic compound exhibiting acidity that can be used as a pharmaceutical additive.
- examples of the organic acid include carboxylic acid, sulfonic acid, enol, or a salt thereof.
- “acidic” means that the pH (hydrogen ion index) in the aqueous solution is less than 7, and “neutral” means that the pH is 7.
- the inorganic acid used in the orally disintegrating tablet of the present invention is not particularly limited as long as it is an inorganic acid that can be added to pharmaceuticals, and examples thereof include hydrochloric acid and phosphoric acid.
- the salt of the inorganic acid used in the orally disintegrating tablet of the present invention is not particularly limited as long as it is a salt of an inorganic acid that can be added to a pharmaceutical product.
- a salt of an inorganic acid that can be added to a pharmaceutical product for example, sodium bisulfite, potassium dihydrogen phosphate, or phosphorus Examples include sodium dihydrogen acid.
- the carboxylic acid used in the orally disintegrating tablet of the present invention is not particularly limited as long as it is a carboxylic acid that can be added to pharmaceuticals.
- Gerare more preferably, aspartic acid, alginic acid, carmellose, or fumaric acid.
- the carboxylic acid salt used in the orally disintegrating tablet of the present invention is not particularly limited as long as it is a carboxylic acid salt that can be added to pharmaceuticals.
- a carboxylic acid salt that can be added to pharmaceuticals.
- the enol used in the orally disintegrating tablet of the present invention is not particularly limited as long as it can be added to a pharmaceutical product, and examples thereof include ascorbic acid or erythorbic acid, and preferably includes ascorbic acid.
- the salt of enol used in the orally disintegrating tablet of the present invention is not particularly limited as long as it can be added to a pharmaceutical product, and examples thereof include sodium ascorbate or sodium erythorbate, and preferably ascorbic acid Sodium is mentioned.
- the amount of the acid (preferably organic acid) contained in the orally disintegrating tablet of the present invention is not particularly limited, but the disintegration test and hardness described in this specification so as to show the desired disintegration and hardness. It is determined appropriately by those skilled in the art with reference to the test standard.
- the amount is preferably 0.1 to 30% by weight, more preferably 0.1 to 15% by weight per 100% by weight of the orally disintegrating tablet.
- water-soluble polymer in the present invention examples include cellulose derivatives such as hydroxypropyl methylcellulose, methylcellulose, hydroxypropylcellulose, sodium carboxymethylcellulose; polyvinylpyrrolidone, aminoalkyl methacrylate copolymer, carboxyvinyl polymer, polyvinyl alcohol, macrogol and the like. And one or a combination of two or more selected from gum arabic, agar, gelatin and sodium alginate.
- the water-soluble polymer used in the present invention is preferably a cellulose derivative, and more preferably hydroxypropylcellulose.
- the content of the water-soluble polymer in the tablet of the present invention is usually 0.1 to 3.0% by weight per 100% by weight of the orally disintegrating tablet from the viewpoints of moldability and disintegration / suspension in water. Preferably, it is 0.1 to 2.0% by weight, particularly 0.1 to 0.7% by weight.
- the content of the water-soluble polymer is too large, the time required for suspension is extended, and the suitability as an orally disintegrating tablet is lowered.
- the orally disintegrating tablet in the present invention may further contain an excipient.
- excipient examples include organic excipients selected from saccharides, sugar alcohols, starches, and celluloses, and inorganic excipients, with sugar alcohols and / or celluloses being preferred.
- saccharide examples include one or a combination of two or more selected from lactose, sucrose, fructooligosaccharide, glucose, palatinose, maltose, reduced maltose, powdered sugar, powdered koji, fructose, isomerized lactose and honey sugar. Can be mentioned.
- sugar alcohol examples include D-mannitol, erythritol, xylitol, maltitol, sorbitol, etc., preferably D-mannitol, erythritol, xylitol, and more preferably D-mannitol.
- D-mannitol those compatible with the pharmacopoeia of Japan, Europe and the United States can be usually used.
- the crystal form, particle size, and specific surface area of D-mannitol to be blended are not particularly limited, but the crystal form may be any of ⁇ -type, ⁇ -type, ⁇ -type, and amorphous, and the particle size is preferably 10 ⁇ m or more and 250 ⁇ m or less.
- the specific surface area is preferably 0.1 m 2 / g or more and 4 m 2 / g or less, more preferably 0.1 m 2 / g or more and 2 m 2 / g or less,
- the crystal form, particle diameter and specific surface area can be measured by, for example, X-ray diffraction method, laser diffraction particle size measurement method, BET specific surface area measurement method (multipoint method), respectively. Examples of commercially available products include D-mannitol from Merck, Rocket, Towa Kasei and Kao.
- the blending amount of the sugar alcohol can be selected as appropriate.
- D-mannitol it is usually 20 to 95% by weight, preferably 30 to 85% by weight per 100% by weight of orally disintegrating tablets.
- the sugar alcohol may be mixed with other ingredients in the form of a powder to form a tablet, and may be compression molded, or may be granulated using an appropriate binder and then subjected to compression molding.
- celluloses include, in addition to crystalline cellulose, one or a combination of two or more selected from powdered cellulose, low-substituted hydroxypropylcellulose, carmellose, carmellose calcium, and croscarmellose sodium.
- the crystalline cellulose typically is a grade having a bulk density of 0.10 ⁇ 0.46g / cm 3, preferably a 0.10 ⁇ 0.42g / cm 3, more preferably 0.10 ⁇ 0.26 g / Cm 3 .
- Examples of commercially available products include Theolas KG-1000 (bulk density 0.10 to 0.15 g / cm 3 ), Theolas KG-802 (bulk density 0.13 to 0.23 g / cm 3 ), Theolas UF-711.
- the blending amount of the crystalline cellulose is preferably 1 to 50% by weight per 100% by weight of the orally disintegrating tablet. When it exceeds 50% by weight, the fluidity is deteriorated and the productivity may be lowered. A more preferable blending amount is 5 to 30% by weight.
- the blending ratio of the crystalline cellulose and the sugar alcohol is 1 to 10 parts by weight, preferably 1.5 to 8.5 parts by weight, more preferably sugar alcohol, based on crystalline cellulose 1. 2 to 3 parts by weight.
- the crystalline cellulose may be mixed with other ingredients in the form of a powder to form a tablet and compression molded, or may be granulated using a suitable binder and then subjected to compression molding.
- starches include one or a combination of two or more selected from corn starch, potato starch, rice starch, and pregelatinized starch.
- examples of the inorganic excipient include one or a combination of two or more selected from synthetic hydrotalcite, precipitated calcium carbonate, hydrous silicon dioxide, light anhydrous silicic acid, magnesium aluminate silicate and magnesium hydroxide. be able to.
- the orally disintegrating tablet in the present invention may further contain a disintegrating agent.
- disintegrants examples include crospovidone (eg, Japanese Pharmacopoeia compatible product), carmellose calcium (eg, Japanese Pharmacopoeia compatible product), carmellose (eg, Japanese Pharmacopoeia compatible product), croscarmellose sodium (eg, Japanese Pharmacopoeia) ), Low-substituted hydroxypropyl cellulose (for example, Japanese Pharmacopoeia compatible product), corn starch (for example, Japanese Pharmacopoeia compatible product), sodium starch glycolate (for example, Japanese Pharmacopoeia compatible product), and alphalation
- crospovidone eg, Japanese Pharmacopoeia compatible product
- carmellose calcium eg, Japanese Pharmacopoeia compatible product
- carmellose eg, Japanese Pharmacopoeia compatible product
- croscarmellose sodium eg, Japanese Pharmacopoeia
- Low-substituted hydroxypropyl cellulose for example, Japanese Pharmacopoeia compatible product
- the above-mentioned pregelatinized starch is a starch that has been pregelatinized by heat treatment, and includes partially pregelatinized starch.
- pregelatinized starch those described in Japanese Pharmaceutical Additive Standard can be used.
- the average degree of pregelatinization is preferably 90% or less, more preferably 70 to 80%.
- pregelatinized starch swelstar PD-1 manufactured by Asahi Kasei Chemicals
- the blended amount of the pregelatinized starch is usually 1 to 15% by weight, preferably 1 to 10% by weight per 100% by weight of the orally disintegrating tablet.
- the pregelatinized starch may be mixed with other ingredients in a powder form to form a tablet, and may be compression molded, or may be granulated together with other ingredients before being subjected to compression molding.
- pregelatinized starch plays a role as a disintegrating agent.
- a liquid for example, water
- it is sprayed on a raw material in a powder state. Then, the granulation proceeds and can be made into granules. Utilizing this property, a powdered mixture containing crystalline cellulose having a bulk density of 0.26 g / cm 3 or less and a sugar alcohol is sprayed with a solution or dispersion in which pregelatinized starch is dissolved or dispersed in water.
- Granules are produced by layer granulation, and if necessary, these are mixed with other components and compression molded to obtain tablets having good moldability and desired orally disintegrating properties.
- Such a manufacturing advantage is a characteristic characteristic of pregelatinized starch that is hardly obtained when conventional disintegrants such as low-substituted hydroxypropylcellulose and crospovidone are used.
- the blending amount of the disintegrant is usually 0.5 to 20% by weight, preferably 2 to 20% by weight per 100% by weight of the orally disintegrating tablet.
- the orally disintegrating tablet of the present invention can contain various additives generally used for tablet production as long as the effect of the invention is not hindered.
- the additive examples include a binder, a lubricant, a coating agent, a plasticizer, a colorant, a flavoring agent, a sweetening agent, a corrigent, a fluidizing agent, a foaming agent, and a surfactant.
- the binder is selected from, for example, gum arabic, sodium alginate, carboxyvinyl polymer, gelatin, dextrin, pectin, sodium polyacrylate, pullulan, methylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinyl alcohol, polyvinylpyrrolidone and macrogol One or a combination of two or more can be mentioned.
- magnesium stearate for example, Japanese Pharmacopoeia compatible product
- calcium stearate for example, Japanese Pharmacopoeia compatible product
- sodium stearyl fumarate for example, pharmaceutical additive standard compatible product
- talc for example, 1 type or a combination of 2 or more types selected from Japanese Pharmacopoeia
- magnesium stearate is particularly preferable.
- the blending amount of the lubricant is preferably 0.1 to 5.0% by weight per 100% by weight of the orally disintegrating tablet.
- Examples of the coating agent for coating the powdery drug surface (crystal surface) or the granulated drug granule surface include ethyl cellulose, aminoalkyl methacrylate copolymer E, methacrylic acid copolymer L, dry methacrylic acid copolymer LD, methacrylic acid, and the like.
- One or more selected from acid copolymer LD, methacrylic acid copolymer S, aminoalkyl methacrylate copolymer RS, aminoalkyl methacrylate copolymer RS, ethyl acrylate / methyl methacrylate copolymer, polyvinyl acetal / diethylamino acetate and polyvinyl acetate resin Can be mentioned.
- plasticizer to be combined with the coating agent examples include one or a combination of two or more selected from diethyl sebacate, dibutyl sebacate, triethyl citrate, stearic acid, polyethylene glycol, and triacetin.
- the colorant is selected from, for example, edible dyes such as edible yellow No. 5, edible red No. 2 and edible blue No. 2; edible lake dyes, yellow ferric oxide, ferric oxide, titanium oxide, ⁇ -carotene and riboflavin One or a combination of two or more can be mentioned.
- Examples of the flavoring agent include one or a combination of two or more selected from orange, lemon, strawberry, mint, menthol, menthol micron, and various flavors.
- sweetener examples include one or a combination of two or more selected from saccharin sodium, saccharin, aspartame, acesulfame potassium, dipotassium glycyrrhizinate, sucralose stevia and thaumatin.
- Examples of the corrigent include one or a combination of two or more selected from sodium chloride, magnesium chloride, disodium inosinate, sodium L-glutamate, and honey.
- Examples of the fluidizing agent include one or a combination of two or more selected from hydrous silicon dioxide, light anhydrous silicic acid, and talc.
- foaming agent examples include tartaric acid and / or anhydrous citric acid.
- surfactant examples include one or a combination of two or more selected from polyoxyl 40 stearate, sorbitan fatty acid ester, polyoxyethylene hydrogenated castor oil, polysorbate, glyceryl monostearate and sodium lauryl sulfate. it can.
- the method for producing the orally disintegrating tablet of the present invention a well-known production method relating to solid preparations can be adopted. For example, after granulation together with the main agent and additives, a lubricant is added and mixed to produce a tablet. By doing so, a tablet can also be obtained. Further, after granulation, operations such as drying and sizing may be performed as necessary.
- aspects A and B of the orally disintegrating tablet of the present invention will be described together with its production method.
- Aspect A Drug-free granule containing crystalline cellulose having a bulk density of 0.26 g / cm 3 or less, sugar alcohol and pregelatinized starch (hereinafter sometimes referred to as fast disintegrating granules) and drug, or drug-containing Orally disintegrating tablet obtained by compression molding of granules.
- the drug-free granules function as a skeleton of a preparation that can impart desirable disintegration properties and moldability as an orally disintegrating tablet.
- Drug-free granules exhibit excellent disintegration and moldability by blending only three components: crystalline cellulose with a bulk density of 0.26 g / cm 3 or less, sugar alcohol, and pregelatinized starch. Depending on the case, other additives may be blended.
- the orally disintegrating tablet in this embodiment has further excellent disintegration and dissolution properties by adding 0.1 to 2.0% by weight of a water-soluble polymer and an organic acid with respect to the total weight of the tablet. Demonstrate.
- the method for producing an orally disintegrating tablet according to aspect A includes a step (A-1) for producing a drug-free granule, a step (A-2) for producing a drug-containing granule, and a drug-free granule, drug or drug-containing A step (A-3) of mixing and compression-molding the granules and other additives is included.
- A-1 Step of producing drug-free granules
- Drug-free granules can be produced using the following method 1) or 2).
- a conventional extrusion granulation method a mixed stirring granulation method, a high speed stirring granulation method, a fluidized bed granulation method, a rolling granulation method, or the like can be used.
- Pregelatinized starch exhibits a viscosity suitable for granulation when dissolved or dispersed in a liquid such as water.
- the granulating method includes a method in which pregelatinized starch is mixed with other components in a powder state and granulated with water, and a method in which pregelatinized starch is granulated with a solution in which water is dissolved or dispersed in water. Either method gives a tablet with the desired properties, preferably the latter method.
- the blending ratio of crystalline cellulose having a bulk density of 0.26 g / cm 3 or less and sugar alcohol is such that when D-mannitol is used as the sugar alcohol, sugar alcohol 1.5 to 8.5 parts by weight, preferably 2 to 3 parts by weight.
- A-2 Process for Producing Drug-Containing Granules
- the drug can be mixed with drug-free granules as it is on the powder or, if desired, after being granulated.
- the drug-containing granule can be produced, for example, by a conventional extrusion granulation method, mixed stirring granulation method, high speed stirring granulation method, fluidized bed granulation method, or rolling granulation method.
- a powdered or granular drug, an organic acid, a crystalline cellulose having a bulk density of 0.26 g / cm 3 or less, and a sugar alcohol mixed powder are prepared using a solution obtained by dissolving or dispersing hydroxypropyl cellulose in water. It can also be granulated into drug-containing granules. Also, a powdered or granular drug, organic acid, mixed powder of crystalline cellulose having a bulk density of 0.26 g / cm 3 or less, sugar alcohol and hydroxypropyl cellulose are granulated with water to form drug-containing granules. You can also.
- Drugs or drug-containing granules can be coated to control unpleasant tastes such as bitterness and irritation, odor masking, and dissolution properties.
- the aforementioned coating agents and plasticizers can be used as appropriate.
- the coating method is performed, for example, by using a fluidized bed granulation / coating machine, a rolling fluidized bed granulation / coating machine, a centrifugal fluidized granulation / coating machine, or a Wurster type fluidized bed granulation / coating machine.
- two or more kinds of drugs When two or more kinds of drugs are used, they can be contained in the same granule or contained in separate granules depending on the suitability of the drugs and used for compression molding.
- A-3 Process of mixing and compression-molding drug-free granules and drug or drug-containing granules, and other additives Drug-free granules and drug or drug-containing granules, and optionally disintegrants, lubricants, other Additives are mixed and compression molded to make an orally disintegrating tablet. Mixing is performed by using, for example, a tumble mixer or a convection mixer. The drug can be mixed with other additives and used as a drug-containing mixed powder.
- the compression molding of the orally disintegrating tablet of the present invention can be performed using a normal tableting machine.
- the molding pressure by the tableting machine may be about the same as that of a normal tablet, and it is preferably about 2 to 20 kN, more preferably about 4 to 14 kN, depending on the shape and size of the tablet.
- the blending ratio of the drug-free granules with respect to the total weight of the tablet components may be 30 to 90%.
- the blending ratio is 30 to 70%, preferably 30 to 60%.
- the blending ratio is 30 to 70%, preferably 30 to 60%.
- the blending weight ratio between the drug-free granule and the drug-containing granule is preferably 0.5 to 2.0 with respect to the drug-containing granule 1.
- Aspect B Orally disintegrating tablet obtained by compression molding a drug-free mixed powder containing crystalline cellulose having a bulk density of 0.26 g / cm 3 or less, sugar alcohol and pregelatinized starch, and drug or drug-containing granules .
- the drug-free mixed powder gives desirable disintegration and moldability as an orally disintegrating tablet.
- the drug-free mixed powder exhibits excellent disintegration and moldability by blending only three components of crystalline cellulose having a bulk density of 0.26 g / cm 3 or less, sugar alcohol, and pregelatinized starch. You may mix
- the orally disintegrating tablet in this embodiment exhibits further superior disintegration and dissolution properties by adding 0.1 to 2.0% by weight of a water-soluble polymer and an organic acid.
- the method for producing an orally disintegrating tablet according to aspect B includes a step of producing a drug-containing granule as required, and a step of mixing and compressing the drug or drug-containing granule and other additives.
- the process for producing the drug-containing granules is the same as A-2 described above.
- the mixing or compression molding step is the same as A-3 described above.
- the orally disintegrating tablet of the present invention thus obtained is excellent in disintegration and solubility when placed in the oral cavity or in water, and is excellent in physical and chemical stability.
- the disintegration property or solubility of the orally disintegrating tablet of the present invention is the disintegration or dissolution time in the oral cavity (until the tablet is completely disintegrated or dissolved in the mouth of a healthy adult male and does not contain water in the mouth only with saliva. Is usually 5 to 180 seconds, preferably 5 to 60 seconds, more preferably about 5 to 40 seconds.
- the orally disintegrating tablet of the present invention is one that gradually disintegrates or dissolves by saliva when it is contained in the mouth, such as pressure in the mouth, that is, pressure by the upper jaw and tongue, or friction by the tongue, that is, “licking” operation, etc. To disintegrate or dissolve in a shorter time. For people who are dry in the mouth or who have little saliva, they can be disintegrated and dissolved in the mouth using water or hot water, or they can be taken with water just like normal tablets. .
- the hardness of the orally disintegrating tablet of the present invention is sufficient even after the stability test under the conditions of constant temperature and humidity (for example, temperature 25 ° C., humidity 75%, open system, 1 week). Have. Therefore, it has a hardness that does not collapse in the manufacturing process and the distribution process of the preparation, has a practical hardness even when stored under conditions of constant temperature and humidity, and is excellent in storage stability.
- the orally disintegrating tablet of the present invention can be used for treatment of diseases as a preparation that is easy to take for the elderly, children, and patients who have difficulty swallowing, and as a safe preparation for general adults.
- a granulated product (drug-containing granule) was obtained by spraying a binding solution obtained by dissolving 12.38 g in purified water 1364 g and drying.
- 18480 g of D-mannitol (Rocket, Pearlitol 50C) and 8360 g of crystalline cellulose (Asahi Kasei Chemicals, Theolas KG-1000) were charged into a fluidized bed granulator / dryer (Pauleck, GPCG-15).
- a granulated product (fast disintegrating granules) was obtained by spraying a solution obtained by dispersing 1100 g of alpha starch (manufactured by Asahi Kasei Chemicals Co., Ltd., swelstar PD-1) in 12650 g of purified water, followed by drying.
- Example 1-1 Fluidized bed granulator (Freund, FLO-2 type), Edoxabantosilate hydrate 392.6 g, D-mannitol (Rocket, Pearlitol 50C) 384.6 g, crystalline cellulose (Asahi Kasei Chemicals, Theolas) UF-711) 95.24 g, fumaric acid (Merck) 5.714 g, crospovidone (BASF, Kollidon CL-F) 57.14 g, and carmellose (Gotoku, NS-300) 57.14 g After spraying a binding solution obtained by dissolving 7.619 g (manufactured by Nippon Soda Co., Ltd., HPC-H) in 839.0 g of purified water, a granulated product (drug-containing granule) was obtained by drying.
- a binding solution obtained by dissolving 7.619 g (manufactured by Nippon Soda Co.,
- the obtained drug-containing granules 600.0 g, fast-disintegrating granules 437.7 g, crospovidone (BASF, Kollidon CL-F) 68.57 g, sucralose (San-Eigen FFI) 13.71 g, and magnesium stearate (Mallinklot, HyQual 5712) 22.86 g was mixed, and then tableted with a rotary tableting machine (Kikusui Seisakusho, VIRGO) at a tableting pressure of 5 kN to obtain an orally disintegrating tablet (11 mm ⁇ , 400 mg) It was.
- Example 1-2 Fluidized bed granulator (Freund, FLO-2 type), Edoxabantosilate hydrate 392.6 g, D-mannitol (Rocket, Pearlitol 50C) 371.2 g, crystalline cellulose (Asahi Kasei Chemicals, Theolas) UF-711) 95.24 g, fumaric acid (Merck) 19.05 g, crospovidone (BASF, Kollidon CL-F) 57.14 g, and carmellose (Gotoku Pharmaceutical, NS-300) 57.14 g were added to hydroxypropylcellulose.
- a granulated product (fast disintegrating granules) was obtained by spraying a solution obtained by dispersing 1100 g of alpha starch (manufactured by Asahi Kasei Chemicals Co., Ltd., swelstar PD-1) in 12650 g of purified water, followed by drying.
- the obtained drug-containing granules 600.0 g, fast-disintegrating granules 437.7 g, crospovidone (BASF, Kollidon CL-F) 68.57 g, sucralose (San-Eigen FFI) 13.71 g, and magnesium stearate (Mallinklot, HyQual 5712) 22.86 g was mixed, and then tableted with a rotary tableting machine (Kikusui Seisakusho, VIRGO) at a tableting pressure of 5 kN to obtain an orally disintegrating tablet (11 mm ⁇ , 400 mg) It was.
- Example 1-3 Fluidized bed granulator (Freund, FLO-2 type), Edoxavantosilate hydrate 384.9 g, D-mannitol (Rocket, Pearlitol 50C) 171.3 g, Crystalline cellulose (Asahi Kasei Chemicals, Theolas) UF-711) 95.24 g, fumaric acid (Merck) 228.6 g, crospovidone (BASF, Kollidon CL-F) 57.14 g, and carmellose (Gotoku, NS-300) 57.14 g (Sponsored by Nippon Soda, HPC-H) After spraying a binding solution obtained by dissolving 5.714 g in 629.2 g of purified water, a granulated product (drug-containing granule) was obtained by drying.
- a granulated product (drug-containing granule) was obtained by spraying a binding solution obtained by dissolving 12.38 g in purified water 1364 g and drying.
- 18480 g of D-mannitol (Rocket, Pearlitol 50C) and 8360 g of crystalline cellulose (Asahi Kasei Chemicals, Theolas KG-1000) were charged into a fluidized bed granulator / dryer (Pauleck, GPCG-15).
- a granulated product (fast disintegrating granules) was obtained by spraying a solution obtained by dispersing 1100 g of alpha starch (manufactured by Asahi Kasei Chemicals Co., Ltd., swelstar PD-1) in 12650 g of purified water, followed by drying.
- Example 2-1 Fluidized bed granulator (Freund, FLO-2 type), Edoxabantosilate hydrate 384.9 g, D-mannitol (Rocket, Pearlitol 50C) 392.3 g, crystalline cellulose (Asahi Kasei Chemicals, Theolas) UF-711) 95.24 g, fumaric acid (Merck) 5.714 g, crospovidone (BASF, Kollidon CL-F) 57.14 g, and carmellose (Gotoku, NS-300) 57.14 g (Sponsored by Nippon Soda, HPC-L) After spraying a binding solution obtained by dissolving 7.619 g in 101.3 g of purified water, a granulated product (drug-containing granule) was obtained by drying.
- FLO-2 type Fluidized bed granulator
- Edoxabantosilate hydrate 384.9 g
- D-mannitol Rocke
- Example 2-2 Fluidized bed granulator (Freund, FLO-2 type), Edoxabantosilate hydrate 392.6 g, D-mannitol (Rocket, Pearlitol 50C) 384.6 g, crystalline cellulose (Asahi Kasei Chemicals, Theolas) UF-711) 95.24 g, fumaric acid (Merck) 5.714 g, crospovidone (BASF, Kollidon CL-F) 57.14 g, and carmellose (Gotoku, NS-300) 57.14 g After spraying a binding solution obtained by dissolving 7.619 g (manufactured by Nippon Soda Co., Ltd., HPC-H) in 839.0 g of purified water, a granulated product (drug-containing granule) was obtained by drying.
- a binding solution obtained by dissolving 7.619 g (manufactured by Nippon Soda Co.,
- the obtained drug-containing granules 600.0 g, fast-disintegrating granules 437.7 g, crospovidone (BASF, Kollidon CL-F) 68.57 g, sucralose (San-Eigen FFI) 13.71 g, and magnesium stearate (Mallinklot, HyQual 5712) 22.86 g was mixed, and then tableted with a rotary tableting machine (Kikusui Seisakusho, VIRGO) at a tableting pressure of 5 kN to obtain an orally disintegrating tablet (11 mm ⁇ , 400 mg) It was.
- a tabletting tablet machine Ichibashi Seiki, HANDTAB
- Example 3-1 Fluidized bed granulator (Freund, FLO-2 type), Edoxabantosilate hydrate 392.6 g, D-mannitol (Rocket, Pearlitol 50C) 371.2 g, crystalline cellulose (Asahi Kasei Chemicals, Theolas) UF-711) 95.24 g, fumaric acid (Merck) 19.05 g, crospovidone (BASF, Kollidon CL-F) 57.14 g, and carmellose (Gotoku Pharmaceutical, NS-300) 57.14 g were added to hydroxypropylcellulose.
- a granulated product (fast disintegrating granules) was obtained by spraying a solution obtained by dispersing 1100 g of alpha starch (manufactured by Asahi Kasei Chemicals Co., Ltd., swelstar PD-1) in 12650 g of purified water, followed by drying.
- the obtained drug-containing granules 600.0 g, fast-disintegrating granules 437.7 g, crospovidone (BASF, Kollidon CL-F) 68.57 g, sucralose (San-Eigen FFI) 13.71 g, and magnesium stearate (Mallinklot, HyQual 5712) 22.86 g was mixed, and then tableted with a rotary tableting machine (Kikusui Seisakusho, VIRGO) at a tableting pressure of 5 kN to obtain an orally disintegrating tablet (11 mm ⁇ , 400 mg) It was.
- Table 1 As in Comparative Example 1-1, when fumaric acid is blended as in Examples 1-1 to 1-3 as compared to a formulation not blended with fumaric acid, it rapidly disintegrates within 60 seconds, Exhibits better function as an orally disintegrating tablet. Moreover, the higher the mixing ratio of fumaric acid, the faster the disintegration time and elution can be secured.
- Example 2- Formulations containing fumaric acid and a small amount of hydroxypropylcellulose, such as 1 and 2-2, exhibit a rapid disintegration time within 60 seconds, and exhibit superior functions as an orally disintegrating tablet To do. Further, at this time, a rapid disintegration time is shown regardless of the physical properties of hydroxypropylcellulose.
- Tables 4 and 5 The orally disintegrating tablets of Example 4 were produced according to the production methods described in Examples 1 to 3 and the formulations described in Table 4. As in Examples 4-1 to 4-9, when fumaric acid, a small amount of hydroxypropylcellulose, and a disintegrant were added to edoxaban, it showed a rapid disintegration time within 60 seconds, which is superior as an orally disintegrating tablet. Function, and quick dissolution can be secured.
- Tables 6 and 7 An example of the formulation of the present invention is described.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
すなわち本発明は、以下の(1)~(24)に関する。
(2)(B)有機酸がフマル酸、アルギン酸、及びアスパラギン酸からなる群から選択される1種以上の成分である(1)に記載の口腔内崩壊錠。
(3)(B)有機酸がフマル酸である(1)に記載の口腔内崩壊錠。
(4)(B)有機酸の含量が錠剤の総重量に対して0.1~15重量%である(1)~(3)のいずれか1項に記載の口腔内崩壊錠。
(5)(C)水溶性高分子がヒドロキシプロピルセルロース、ヒドロキシプロピルメチルセルロース、メチルセルロース、ポリビニルピロリドン、及びポリビニルアルコールからなる群から選択される1種以上の成分である(1)~(4)のいずれか1項に記載の口腔内崩壊錠。
(7)(D)崩壊剤がカルメロース、クロスポビドン、カルメロースカルシウム、クロスカルメロースナトリウム、トウモロコシデンプン、デンプングリコール酸ナトリウム、及びアルファー化デンプンからなる群から選択される1種以上の成分である(1)~(6)のいずれか1項に記載の口腔内崩壊錠。
(8)(D)崩壊剤がカルメロース、クロスポビドン、及びアルファー化デンプンである(1)~(6)のいずれか1項に記載の口腔内崩壊錠。
(9)さらに糖アルコール及びかさ密度が0.26g/cm3以下の結晶セルロースを含む(7)又は(8)に記載の口腔内崩壊錠。
(10)糖アルコールがD-マンニトールである(9)に記載の口腔内崩壊錠。
(12)(A)エドキサバン、その薬理上許容される塩、又はそれらの溶媒和物、(B)有機酸、(C)錠剤の総重量に対して0.1~2.0重量%のヒドロキシプロピルセルロース、(E)カルメロース、(F)D-マンニトール、(G)かさ密度が0.26g/cm3以下の結晶セルロース、及び(H)アルファー化デンプンを含有する口腔内崩壊錠。
(13)(A)エドキサバン、その薬理上許容される塩、又はそれらの溶媒和物、(B)有機酸、(C)錠剤の総重量に対して0.1~2.0重量%のヒドロキシプロピルセルロース、及び(E)カルメロースを含有する薬物含有混合末又は薬物含有顆粒と、(F)D-マンニトール、(G)かさ密度が0.26g/cm3以下の結晶セルロース、及び(H)アルファー化デンプンを含有する薬物不含有混合末とを含有する(12)に記載の口腔内崩壊錠。
(14)(A)エドキサバン、その薬理上許容される塩、又はそれらの溶媒和物、(B)有機酸、(C)錠剤の総重量に対して0.1~2.0重量%のヒドロキシプロピルセルロース、及び(E)カルメロースを含有する薬物含有混合末、又は薬物含有顆粒と(F)D-マンニトール、(G)かさ密度が0.26g/cm3以下の結晶セルロース、及び(H)アルファー化デンプンを含有する薬物不含有顆粒とを含有する(12)に記載の口腔内崩壊錠。
(15)(A)エドキサバン、その薬理上許容される塩、又はそれらの溶媒和物、(B)有機酸、(C)錠剤の総重量に対して0.1~2.0重量%のヒドロキシプロピルセルロース、及び(E)カルメロースを含有する薬物含有顆粒と、(F)D-マンニトール、(G)かさ密度が0.26g/cm3以下の結晶セルロース、及び(H)アルファー化デンプンを含有する薬物不含有顆粒とを含有する(12)に記載の口腔内崩壊錠。
(17)(B)有機酸がフマル酸である(12)~(15)のいずれか1項に記載の口腔内崩壊錠。
(18)さらにクロスポビドン、カルメロースカルシウム、クロスカルメロースナトリウム、トウモロコシデンプン、デンプングリコール酸ナトリウム、及びアルファー化デンプンからなる群から選ばれる1種以上の成分を含む(12)~(17)のいずれか1項に記載の口腔内崩壊錠。
(19)さらにクロスポビドンを含む請求項(12)~(17)のいずれか1項に記載の口腔内崩壊錠。
(20)有機酸が錠剤の総重量に対して0.1~15重量%である(12)~(19)のいずれか1項に記載の口腔内崩壊錠。
(22)アルファー化デンプンの平均アルファー化度が90%以下である請求項(12)~(21)のいずれか1項に記載の口腔内崩壊錠。
(23)崩壊試験において60秒以内に崩壊する請求項(12)~(22)のいずれか1項に記載の口腔内崩壊錠。
(24)(A)エドキサバン、その薬理上許容される塩、又はそれらの溶媒和物、(B)フマル酸及び(E)カルメロースを混合し、水に溶解した(C)錠剤の総重量に対して0.1~2.0重量%のヒドロキシプロピルセルロースを噴霧することによって薬物含有顆粒を製造する工程、(F)D-マンニトール及び(G)かさ密度が0.26g/cm3以下の結晶セルロースを混合し、水に溶解または分散した(H)アルファー化デンプンを噴霧することによって薬物不含有顆粒を製造する工程、並びに得られた2種類の顆粒を圧縮成形する工程を含む口腔内崩壊錠の製造方法。
(25)(A)エドキサバン、その薬理上許容される塩、又はそれらの溶媒和物、(B)フマル酸、(C)錠剤の総重量に対して0.1~2.0重量%のヒドロキシプロピルセルロース、及び(E)カルメロースを混合し、水を噴霧することによって薬物含有顆粒を製造する工程、(F)D-マンニトール及び(G)かさ密度が0.26g/cm3以下の結晶セルロースを混合し、水に溶解または分散した(H)アルファー化デンプンを噴霧することによって薬物不含有顆粒を製造する工程、並びに得られた2種類の顆粒を圧縮成形する工程を含む口腔内崩壊錠の製造方法。
糖類としては、例えば、乳糖、ショ糖、フラクトオリゴ糖、ブドウ糖、パラチノース、マルトース、還元麦芽糖、粉糖、粉末飴、果糖、異性化乳糖及び蜂蜜糖から選択される1つ又は2つ以上の組み合わせを挙げることができる。
上記アルファー化デンプンの配合量は、口腔内崩壊錠100重量%当たり、通常1~15重量%であり、好ましくは、1~10重量%である。
以下の1)または2)の方法を用いて、薬物不含有顆粒を製造することができる。
薬物は、粉末上のまま、あるいは所望により顆粒状にしてから、薬物不含有顆粒と混合することができる。薬物含有顆粒は、例えば、慣用の押し出し造粒法、混合攪拌造粒法、高速攪拌造粒法、流動層造粒法、又は転動造粒法で製造できる。
薬物不含有顆粒と薬物又は薬物含有顆粒、及び所望により崩壊剤、滑沢剤、その他の添加剤を混合し圧縮成形して口腔内崩壊錠とする。混合は、例えば、タンブルミキサー、対流式ミキサーを用いることで行われる。薬物はその他の添加剤と混合し、薬物含有混合末として使用することもできる。
一方、本発明の口腔内崩壊錠の硬度は、一定の温度、湿度の条件下(例えば、温度25℃、湿度75%、開放系、1週間)の安定性試験の後にも、十分な硬度を有する。
従って、製剤の製造工程及び流通過程において崩れない硬度を有し、一定の温度、湿度の条件下での保存においても実用的な硬度を有し、保存安定性にも優れている。
[比較例1-1]
流動層造粒乾燥機(フロイント社製、FLO-2型)に、エドキサバントシル酸塩水和物384.9 g、D-マンニトール(ロケット社製、Pearlitol 50C)355.1 g、結晶セルロース(旭化成ケミカルズ社製、セオラスUF-711)95.24 g、クロスポビドン(BASF社製、Kollidon CL-F)95.24 g、及びカルメロース(五徳薬品製、NS-300)57.14 gを投入し、ヒドロキシプロピルセルロース(日本曹達製、HPC-H)12.38 gを精製水1364 gに溶解した結合液を噴霧後、乾燥することで造粒物(薬物含有顆粒)を得た。また、流動層造粒乾燥機(パウレック製、GPCG-15)に、D-マンニトール(ロケット社製、Pearlitol 50C)18480 g、結晶セルロース(旭化成ケミカルズ製、セオラスKG-1000)8360 gを投入し、アルファー化デンプン(旭化成ケミカルズ製、swelstar PD-1)1100 gを精製水12650 gに分散した液を噴霧後、乾燥することで造粒物(速崩壊性顆粒)を得た。さらに、得られた薬物含有顆粒600.0 g、速崩壊性顆粒451.4 g、クロスポビドン(BASF社製、Kollidon CL-F)68.57 g、及びステアリン酸マグネシウム(マリンクロット製、HyQual 5712)22.86 gを混合後、ロータリー打錠機(菊水製作所、VIRGO)にて、打錠圧5 kNで打錠を行い、口腔内崩壊錠(11 mmφ、400mg)を得た。
流動層造粒乾燥機(フロイント製、FLO-2型)に、エドキサバントシル酸塩水和物392.6 g、D-マンニトール(ロケット社製、Pearlitol 50C)384.6 g、結晶セルロース(旭化成ケミカルズ製、セオラスUF-711)95.24 g、フマル酸(メルク製)5.714 g、クロスポビドン(BASF製、Kollidon CL-F)57.14 g、及びカルメロース(五徳薬品製、NS-300)57.14 gを投入し、ヒドロキシプロピルセルロース(日本曹達製、HPC-H)7.619 gを精製水839.0 gに溶解した結合液を噴霧後、乾燥することで造粒物(薬物含有顆粒)を得た。また、流動層造粒乾燥機(パウレック製、GPCG-15)に、D-マンニトール(ロケット社製、Pearlitol 50C)18480 g、結晶セルロース(旭化成ケミカルズ製、セオラスKG-1000)8360 gを投入し、アルファー化デンプン(旭化成ケミカルズ製、swelstar PD-1)1100 gを精製水12650 gに分散した液を噴霧後、乾燥することで造粒物(速崩壊性顆粒)を得た。さらに、得られた薬物含有顆粒600.0 g、速崩壊性顆粒437.7 g、クロスポビドン(BASF製、Kollidon CL-F)68.57 g、スクラロース(三栄源エフ・エフ・アイ製)13.71 g、及びステアリン酸マグネシウム(マリンクロット製、HyQual 5712)22.86 gを混合後、ロータリー打錠機(菊水製作所、VIRGO)にて、打錠圧5 kNで打錠を行い、口腔内崩壊錠(11 mmφ、400mg)を得た。
流動層造粒乾燥機(フロイント製、FLO-2型)に、エドキサバントシル酸塩水和物392.6 g、D-マンニトール(ロケット社製、Pearlitol 50C)371.2 g、結晶セルロース(旭化成ケミカルズ製、セオラスUF-711)95.24 g、フマル酸(メルク製)19.05 g、クロスポビドン(BASF製、Kollidon CL-F)57.14 g、及びカルメロース(五徳薬品製、NS-300)57.14 gを投入し、ヒドロキシプロピルセルロース(日本曹達製、HPC-H)7.619 gを精製水839.0 gに溶解した結合液を噴霧後、乾燥することで造粒物(薬物含有顆粒)を得た。また、流動層造粒乾燥機(パウレック製、GPCG-15)に、D-マンニトール(ロケット社製、Pearlitol 50)18480 g、結晶セルロース(旭化成ケミカルズ製、セオラスKG-1000)8360 gを投入し、アルファー化デンプン(旭化成ケミカルズ製、swelstar PD-1)1100 gを精製水12650 gに分散した液を噴霧後、乾燥することで造粒物(速崩壊性顆粒)を得た。さらに、得られた薬物含有顆粒600.0 g、速崩壊性顆粒437.7 g、クロスポビドン(BASF製、Kollidon CL-F)68.57 g、スクラロース(三栄源エフ・エフ・アイ製)13.71 g、及びステアリン酸マグネシウム(マリンクロット製、HyQual 5712)22.86 gを混合後、ロータリー打錠機(菊水製作所、VIRGO)にて、打錠圧5 kNで打錠を行い、口腔内崩壊錠(11 mmφ、400mg)を得た。
流動層造粒乾燥機(フロイント製、FLO-2型)に、エドキサバントシル酸塩水和物384.9 g、D-マンニトール(ロケット社製、Pearlitol 50C)171.3 g、結晶セルロース(旭化成ケミカルズ製、セオラスUF-711)95.24 g、フマル酸(メルク製)228.6 g、クロスポビドン(BASF製、Kollidon CL-F)57.14 g、及びカルメロース(五徳薬品製、NS-300)57.14 gを投入し、ヒドロキシプロピルセルロース(日本曹達製、HPC-H)5.714 gを精製水629.2 gに溶解した結合液を噴霧後、乾燥することで造粒物(薬物含有顆粒)を得た。また、流動層造粒乾燥機(パウレック製、GPCG-15)に、D-マンニトール(ロケット社製、Pearlitol 50C)18480 g、結晶セルロース(旭化成ケミカルズ製、セオラスKG-1000)8360 gを投入し、アルファー化デンプン(旭化成ケミカルズ製、swelstar PD-1)1100 gを精製水12650 gに分散した液を噴霧後、乾燥することで造粒物(速崩壊性顆粒)を得た。さらに、得られた薬物含有顆粒600.0 g、速崩壊性顆粒451.4 g、クロスポビドン(BASF製、Kollidon CL-F)68.57 g、及びステアリン酸マグネシウム(マリンクロット製、HyQual 5712)22.86 gを混合後、ロータリー打錠機(菊水製作所、VIRGO)にて、打錠圧5 kNで打錠を行い、口腔内崩壊錠(11 mmφ、400mg)を得た。
流動層造粒乾燥機(フロイント社製、FLO-2型)に、エドキサバントシル酸塩水和物384.9 g、D-マンニトール(ロケット社製、Pearlitol 50C)355.1 g、結晶セルロース(旭化成ケミカルズ社製、セオラスUF-711)95.24 g、クロスポビドン(BASF社製、Kollidon CL-F)95.24 g、及びカルメロース(五徳薬品製、NS-300)57.14 gを投入し、ヒドロキシプロピルセルロース(日本曹達製、HPC-H)12.38 gを精製水1364 gに溶解した結合液を噴霧後、乾燥することで造粒物(薬物含有顆粒)を得た。また、流動層造粒乾燥機(パウレック製、GPCG-15)に、D-マンニトール(ロケット社製、Pearlitol 50C)18480 g、結晶セルロース(旭化成ケミカルズ製、セオラスKG-1000)8360 gを投入し、アルファー化デンプン(旭化成ケミカルズ製、swelstar PD-1)1100 gを精製水12650 gに分散した液を噴霧後、乾燥することで造粒物(速崩壊性顆粒)を得た。さらに、得られた薬物含有顆粒600.0 g、速崩壊性顆粒451.4 g、クロスポビドン(BASF社製、Kollidon CL-F)68.57 g、及びステアリン酸マグネシウム(マリンクロット製、HyQual 5712)22.86 gを混合後、ロータリー打錠機(菊水製作所、VIRGO)にて、打錠圧5 kNで打錠を行い、口腔内崩壊錠(11 mmφ、400mg)を得た。
流動層造粒乾燥機(フロイント製、FLO-2型)に、エドキサバントシル酸塩水和物384.9 g、D-マンニトール(ロケット社製、Pearlitol 50C)352.3 g、結晶セルロース(旭化成ケミカルズ製、セオラスUF-711)95.24 g、フマル酸(メルク製)5.714 g、クロスポビドン(BASF製、Kollidon CL-F)57.14 g、及びカルメロース(五徳薬品製、NS-300)57.14 gを投入し、ヒドロキシプロピルセルロース(日本曹達製、HPC-L)47.62 gを精製水632.9 gに溶解した結合液を噴霧後、乾燥することで造粒物(薬物含有顆粒)を得た。また、流動層造粒乾燥機(パウレック製、GPCG-15)に、D-マンニトール(ロケット社製、Pearlitol 50C)18480 g、結晶セルロース(旭化成ケミカルズ製、セオラスKG-1000)8360 gを投入し、アルファー化デンプン(旭化成ケミカルズ製、swelstar PD-1)1100 gを精製水12650 gに分散した液を噴霧後、乾燥することで造粒物(速崩壊性顆粒)を得た。さらに、得られた薬物含有顆粒330.0 g、速崩壊性顆粒248.3 g、クロスポビドン(BASF製、Kollidon CL-F)37.71 g、及びステアリン酸マグネシウム(マリンクロット製、HyQual 5712)12.60 gを混合後、ロータリー打錠機(菊水製作所、18HUK)にて、打錠圧5 kNで打錠を行い、口腔内崩壊錠(11 mmφ、400mg)を得た。
流動層造粒乾燥機(フロイント製、FLO-2型)に、エドキサバントシル酸塩水和物384.9 g、D-マンニトール(ロケット社製、Pearlitol 50C)352.3 g、結晶セルロース(旭化成ケミカルズ製、セオラスUF-711)95.24 g、フマル酸(メルク製)5.714 g、クロスポビドン(BASF製、Kollidon CL-F)57.14 g、及びカルメロース(五徳薬品製、NS-300)57.14 gを投入し、ヒドロキシプロピルセルロース(日本曹達製、HPC-H)47.62 gを精製水3920 gに溶解した結合液を噴霧後、乾燥することで造粒物(薬物含有顆粒)を得た。また、流動層造粒乾燥機(パウレック製、GPCG-15)に、D-マンニトール(ロケット社製、Pearlitol 50C)18480 g、結晶セルロース(旭化成ケミカルズ製、セオラスKG-1000)8360 gを投入し、アルファー化デンプン(旭化成ケミカルズ製、swelstar PD-1)1100 gを精製水12650 gに分散した液を噴霧後、乾燥することで造粒物(速崩壊性顆粒)を得た。さらに、得られた薬物含有顆粒330.0 g、速崩壊性顆粒248.3 g、クロスポビドン(BASF製、Kollidon CL-F)37.71 g、及びステアリン酸マグネシウム(マリンクロット製、HyQual 5712)12.60 gを混合後、ロータリー打錠機(菊水製作所、18HUK)にて、打錠圧5 kNで打錠を行い、口腔内崩壊錠(11 mmφ、400mg)を得た。
流動層造粒乾燥機(フロイント製、FLO-2型)に、エドキサバントシル酸塩水和物384.9 g、D-マンニトール(ロケット社製、Pearlitol 50C)392.3 g、結晶セルロース(旭化成ケミカルズ製、セオラスUF-711)95.24 g、フマル酸(メルク製)5.714 g、クロスポビドン(BASF製、Kollidon CL-F)57.14 g、及びカルメロース(五徳薬品製、NS-300)57.14 gを投入し、ヒドロキシプロピルセルロース(日本曹達製、HPC-L)7.619 gを精製水101.3 gに溶解した結合液を噴霧後、乾燥することで造粒物(薬物含有顆粒)を得た。また、流動層造粒乾燥機(パウレック製、GPCG-15)に、D-マンニトール(ロケット社製、Pearlitol 50C)18480 g、結晶セルロース(旭化成ケミカルズ製、セオラスKG-1000)8360 gを投入し、アルファー化デンプン(旭化成ケミカルズ製、swelstar PD-1)1100 gを精製水12650 gに分散した液を噴霧後、乾燥することで造粒物(速崩壊性顆粒)を得た。さらに、得られた薬物含有顆粒330.0 g、速崩壊性顆粒248.3 g、クロスポビドン(BASF製、Kollidon CL-F)37.71 g、及びステアリン酸マグネシウム(マリンクロット製、HyQual 5712)12.60 gを混合後、ロータリー打錠機(菊水製作所、18HUK)にて、打錠圧5 kNで打錠を行い、口腔内崩壊錠(11 mmφ、400mg)を得た。
流動層造粒乾燥機(フロイント製、FLO-2型)に、エドキサバントシル酸塩水和物392.6 g、D-マンニトール(ロケット社製、Pearlitol 50C)384.6 g、結晶セルロース(旭化成ケミカルズ製、セオラスUF-711)95.24 g、フマル酸(メルク製)5.714 g、クロスポビドン(BASF製、Kollidon CL-F)57.14 g、及びカルメロース(五徳薬品製、NS-300)57.14 gを投入し、ヒドロキシプロピルセルロース(日本曹達製、HPC-H)7.619 gを精製水839.0 gに溶解した結合液を噴霧後、乾燥することで造粒物(薬物含有顆粒)を得た。また、流動層造粒乾燥機(パウレック製、GPCG-15)に、D-マンニトール(ロケット社製、Pearlitol 50C)18480 g、結晶セルロース(旭化成ケミカルズ製、セオラスKG-1000)8360 gを投入し、アルファー化デンプン(旭化成ケミカルズ製、swelstar PD-1)1100 gを精製水12650 gに分散した液を噴霧後、乾燥することで造粒物(速崩壊性顆粒)を得た。さらに、得られた薬物含有顆粒600.0 g、速崩壊性顆粒437.7 g、クロスポビドン(BASF製、Kollidon CL-F)68.57 g、スクラロース(三栄源エフ・エフ・アイ製)13.71 g、及びステアリン酸マグネシウム(マリンクロット製、HyQual 5712)22.86 gを混合後、ロータリー打錠機(菊水製作所、VIRGO)にて、打錠圧5 kNで打錠を行い、口腔内崩壊錠(11 mmφ、400mg)を得た。
エドキサバントシル酸塩水和物16.16 g、D-マンニトール(ロケット社製、Pearlitol 50C)15.92 g、及び結晶セルロース(旭化成ケミカルズ社製、セオラスUF-711)4.0 gを乳鉢を用いて混合することで混合物(薬物含有混合末)を得た。得られた薬物含有混合末36.08 g、及びステアリン酸マグネシウム(マリンクロット製、HyQual 5712)0.72 gを混合し、更にフマル酸(日本触媒製)0.1 g、及びヒドロキシプロピルセルロース(日本曹達製、HPC-L)0.1 gを混合した後、卓上錠剤成形機(市橋精機、HANDTAB)にて、打錠圧10 kNで打錠を行い、口腔内崩壊錠(8.0 mmφ、194 mg)を得た。
エドキサバントシル酸塩水和物16.16 g、D-マンニトール(ロケット社製、Pearlitol 50C)15.92 g、及び結晶セルロース(旭化成ケミカルズ社製、セオラスUF-711)4.0 gを乳鉢を用いて混合することで混合物(薬物含有混合末)を得た。得られた薬物含有混合末36.08 g及びステアリン酸マグネシウム(マリンクロット製、HyQual 5712)0.72 gを混合し、更にクロスポビドン(BASF社製、Kollidon CL-F)0.1 g及びカルメロース(五徳薬品製、NS-300)0.1 gを混合した後、卓上錠剤成形機(市橋精機、HANDTAB)にて、打錠圧10 kNで打錠を行い、口腔内崩壊錠(8.0 mmφ、194 mg)を得た。
流動層造粒乾燥機(フロイント製、FLO-2型)に、エドキサバントシル酸塩水和物392.6 g、D-マンニトール(ロケット社製、Pearlitol 50C)371.2 g、結晶セルロース(旭化成ケミカルズ製、セオラスUF-711)95.24 g、フマル酸(メルク製)19.05 g、クロスポビドン(BASF製、Kollidon CL-F)57.14 g、及びカルメロース(五徳薬品製、NS-300)57.14 gを投入し、ヒドロキシプロピルセルロース(日本曹達製、HPC-H)7.619 gを精製水839.0 gに溶解した結合液を噴霧後、乾燥することで造粒物(薬物含有顆粒)を得た。また、流動層造粒乾燥機(パウレック製、GPCG-15)に、D-マンニトール(ロケット社製、Pearlitol 50)18480 g、結晶セルロース(旭化成ケミカルズ製、セオラスKG-1000)8360 gを投入し、アルファー化デンプン(旭化成ケミカルズ製、swelstar PD-1)1100 gを精製水12650 gに分散した液を噴霧後、乾燥することで造粒物(速崩壊性顆粒)を得た。さらに、得られた薬物含有顆粒600.0 g、速崩壊性顆粒437.7 g、クロスポビドン(BASF製、Kollidon CL-F)68.57 g、スクラロース(三栄源エフ・エフ・アイ製)13.71 g、及びステアリン酸マグネシウム(マリンクロット製、HyQual 5712)22.86 gを混合後、ロータリー打錠機(菊水製作所、VIRGO)にて、打錠圧5 kNで打錠を行い、口腔内崩壊錠(11 mmφ、400mg)を得た。
実施例及び比較例で得た錠剤について、以下の方法で評価を行った。
錠厚、及び硬度は、全自動錠剤測定装置(Type WHT-2、PHARMA TEST APPARATEBAU GmbH)を用いて測定した(20錠の平均値を記載)。
崩壊試験は、第十六改正日本薬局方の『崩壊試験法』を参考にし、測定した(6錠の個々最大値を記載)。
溶出性試験は、日本薬局方に記載の第2法(パドル法、50 rpm)に従った。溶出率は、錠剤6個の平均溶出率を算出した。溶出試験液(pH 6.0)には、リン酸水素二ナトリウム溶液(0.05 mol/L)に、クエン酸溶液(0.025 mol/L)を適量加え、pH 6.0 に調整して用いた。
[結果の簡単な説明]
表1:比較例1-1のように、フマル酸を配合しない処方と比較して実施例1-1~1-3のように、フマル酸を配合すると、60秒以内に速やかに崩壊し、口腔内崩壊錠としてのより優れた機能を発揮する。また、フマル酸の配合比率が高いほど、より速やかな崩壊時間及び溶出性が確保できる。
Claims (21)
- (A)エドキサバン、その薬理上許容される塩、又はそれらの溶媒和物、(B)有機酸、(C)錠剤の総重量に対して0.1~2.0重量%の水溶性高分子、及び(D)崩壊剤を含有する口腔内崩壊錠。
- (B)有機酸がフマル酸、アルギン酸、及びアスパラギン酸からなる群から選択される1種以上の成分である請求項1に記載の口腔内崩壊錠。
- (B)有機酸がフマル酸である請求項1に記載の口腔内崩壊錠。
- (B)有機酸の含量が錠剤の総重量に対して0.1~15重量%である請求項1~3のいずれか1項に記載の口腔内崩壊錠。
- (C)水溶性高分子がヒドロキシプロピルセルロース、ヒドロキシプロピルメチルセルロース、メチルセルロース、ポリビニルピロリドン、及びポリビニルアルコールからなる群から選択される1種以上の成分である請求項1~4のいずれか1項に記載の口腔内崩壊錠。
- (C)水溶性高分子がヒドロキシプロピルセルロースである請求項1~4のいずれか1項に記載の口腔内崩壊錠。
- (D)崩壊剤がカルメロース、クロスポビドン、カルメロースカルシウム、クロスカルメロースナトリウム、トウモロコシデンプン、デンプングリコール酸ナトリウム、及びアルファー化デンプンからなる群から選択される1種以上の成分である請求項1~6のいずれか1項に記載の口腔内崩壊錠。
- (D)崩壊剤がカルメロース、クロスポビドン、及びアルファー化デンプンである請求項1~6のいずれか1項に記載の口腔内崩壊錠。
- さらに糖アルコール及びかさ密度が0.26g/cm3以下の結晶セルロースを含む請求項7又は8に記載の口腔内崩壊錠。
- 糖アルコールがD-マンニトールである請求項9に記載の口腔内崩壊錠。
- (A)エドキサバン、その薬理上許容される塩、又はそれらの溶媒和物、(B)有機酸、(C)錠剤の総重量に対して0.1~2.0重量%のヒドロキシプロピルセルロース、(E)カルメロース、(F)D-マンニトール、(G)かさ密度が0.26g/cm3以下の結晶セルロース、及び(H)アルファー化デンプンを含有する口腔内崩壊錠。
- (A)エドキサバン、その薬理上許容される塩、又はそれらの溶媒和物、(B)有機酸、(C)錠剤の総重量に対して0.1~2.0重量%のヒドロキシプロピルセルロース、及び(E)カルメロースを含有する薬物含有混合末又は薬物含有顆粒と、(F)D-マンニトール、(G)かさ密度が0.26g/cm3以下の結晶セルロース、及び(H)アルファー化デンプンを含有する薬物不含有混合末とを含有する請求項11に記載の口腔内崩壊錠。
- (A)エドキサバン、その薬理上許容される塩、又はそれらの溶媒和物、(B)有機酸、(C)錠剤の総重量に対して0.1~2.0重量%のヒドロキシプロピルセルロース、及び(E)カルメロースを含有する薬物含有混合末又は薬物含有顆粒と、(F)D-マンニトール、(G)かさ密度が0.26g/cm3以下の結晶セルロース、及び(H)アルファー化デンプンを含有する薬物不含有顆粒とを含有する請求項11に記載の口腔内崩壊錠。
- (B)有機酸がフマル酸、アルギン酸、及びアスパラギン酸からなる群から選択される1種以上の成分である請求項11~13のいずれか1項に記載の口腔内崩壊錠。
- (B)有機酸がフマル酸である請求項11~13のいずれか1項に記載の口腔内崩壊錠。
- さらにクロスポビドン、カルメロースカルシウム、クロスカルメロースナトリウム、トウモロコシデンプン、デンプングリコール酸ナトリウム、及びアルファー化デンプンからなる群から選択される1種以上の成分を含む請求項11~15のいずれか1項に記載の口腔内崩壊錠。
- さらにクロスポビドンを含む請求項11~15のいずれか1項に記載の口腔内崩壊錠。
- (B)有機酸が錠剤の総重量に対して0.1~15重量%である請求項11~17のいずれか1項に記載の口腔内崩壊錠。
- 崩壊試験において60秒以内に崩壊する請求項11~18のいずれか1項に記載の口腔内崩壊錠。
- (A)エドキサバン、その薬理上許容される塩、又はそれらの溶媒和物、(B)フマル酸及び(E)カルメロースを混合し、水に溶解した(C)錠剤の総重量に対して0.1~2.0重量%のヒドロキシプロピルセルロースを噴霧することによって薬物含有顆粒を製造する工程、(F)D-マンニトール及び(G)かさ密度が0.26g/cm3以下の結晶セルロースを混合し、水に溶解または分散した(H)アルファー化デンプンを噴霧することによって薬物不含有顆粒を製造する工程、並びに得られた2種類の顆粒を圧縮成形する工程を含む口腔内崩壊錠の製造方法。
- (A)エドキサバン、その薬理上許容される塩、又はそれらの溶媒和物、(B)フマル酸、(C)錠剤の総重量に対して0.1~2.0重量%のヒドロキシプロピルセルロース、及び(E)カルメロースを混合し、水を噴霧することによって薬物含有顆粒を製造する工程、(F)D-マンニトール及び(G)かさ密度が0.26g/cm3以下の結晶セルロースを混合し、水に溶解または分散した(H)アルファー化デンプンを噴霧することによって薬物不含有顆粒を製造する工程、並びに得られた2種類の顆粒を圧縮成形する工程を含む口腔内崩壊錠の製造方法。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018554219A JP7096164B2 (ja) | 2016-12-01 | 2017-11-30 | ジアミン誘導体を含む口腔内崩壊錠 |
EP17875830.6A EP3549585B1 (en) | 2016-12-01 | 2017-11-30 | Orally disintegrating tablet of edoxaban tosylate hydrate |
BR112019011169A BR112019011169A2 (pt) | 2016-12-01 | 2017-11-30 | comprimido de desintegração oral incluindo derivado de diamina |
CN201780074493.5A CN109996542A (zh) | 2016-12-01 | 2017-11-30 | 包含二胺衍生物的口腔崩解片 |
CA3045418A CA3045418C (en) | 2016-12-01 | 2017-11-30 | Orally disintegrating tablet comprising edoxaban |
KR1020197015485A KR102631488B1 (ko) | 2016-12-01 | 2017-11-30 | 디아민 유도체를 함유하는 구강내 붕괴정 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016234259 | 2016-12-01 | ||
JP2016-234259 | 2016-12-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018101373A1 true WO2018101373A1 (ja) | 2018-06-07 |
Family
ID=62241764
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2017/042930 WO2018101373A1 (ja) | 2016-12-01 | 2017-11-30 | ジアミン誘導体を含む口腔内崩壊錠 |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP3549585B1 (ja) |
JP (1) | JP7096164B2 (ja) |
KR (1) | KR102631488B1 (ja) |
CN (1) | CN109996542A (ja) |
BR (1) | BR112019011169A2 (ja) |
CA (1) | CA3045418C (ja) |
TW (1) | TWI812602B (ja) |
WO (1) | WO2018101373A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021017410A (ja) * | 2019-07-19 | 2021-02-15 | 日医工株式会社 | エドキサバン含有医薬組成物 |
WO2022024979A1 (ja) * | 2020-07-27 | 2022-02-03 | 第一三共株式会社 | ミロガバリンベシル酸塩を含有する口腔内崩壊錠 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2020384737A1 (en) * | 2019-11-13 | 2022-05-26 | Unison Pharmaceuticals Pvt. Ltd. | Orally disintegrating pharmaceutical compositions of apixaban |
WO2022129535A1 (en) | 2020-12-18 | 2022-06-23 | Krka, D.D., Novo Mesto | Edoxaban formulation containing no sugar alcohols |
CA3234371A1 (en) | 2021-11-22 | 2023-05-25 | Intas Pharmaceuticals Ltd. | An orodispersible pharmaceutical dosage form of edoxaban |
EP4183390A1 (en) | 2021-11-22 | 2023-05-24 | Intas Pharmaceuticals Limited | An orodispersible pharmaceutical dosage form of edoxaban |
WO2024121413A1 (en) * | 2022-12-09 | 2024-06-13 | Synthon B.V. | Formulation comprising edoxaban and preparation thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102058889A (zh) * | 2010-11-05 | 2011-05-18 | 王定豪 | 包含抗凝血类药物的分散片及其应用 |
WO2013022059A1 (ja) * | 2011-08-10 | 2013-02-14 | 第一三共株式会社 | ジアミン誘導体含有医薬組成物 |
JP5295506B2 (ja) | 2006-02-21 | 2013-09-18 | 第一三共株式会社 | レボフロキサシン含有錠剤 |
WO2013161823A1 (ja) * | 2012-04-24 | 2013-10-31 | 第一三共株式会社 | 口腔内崩壊錠及びその製造方法 |
US9149532B2 (en) | 2007-03-29 | 2015-10-06 | Daiichi Sanykyo Company, Limited | Pharmaceutical composition |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5440170Y2 (ja) | 1976-01-13 | 1979-11-27 | ||
ES2706880T3 (es) * | 2010-02-22 | 2019-04-01 | Daiichi Sankyo Co Ltd | Preparación sólida de liberación sostenida para uso oral |
EP2540317A4 (en) * | 2010-02-22 | 2014-04-16 | Daiichi Sankyo Co Ltd | SOLID PREPARATION WITH DELAYED RELEASE FOR ORAL ADMINISTRATION |
WO2013022924A1 (en) * | 2011-08-08 | 2013-02-14 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical formulations |
-
2017
- 2017-11-29 TW TW106141525A patent/TWI812602B/zh active
- 2017-11-30 KR KR1020197015485A patent/KR102631488B1/ko active IP Right Grant
- 2017-11-30 JP JP2018554219A patent/JP7096164B2/ja active Active
- 2017-11-30 EP EP17875830.6A patent/EP3549585B1/en active Active
- 2017-11-30 CA CA3045418A patent/CA3045418C/en active Active
- 2017-11-30 BR BR112019011169A patent/BR112019011169A2/pt unknown
- 2017-11-30 CN CN201780074493.5A patent/CN109996542A/zh active Pending
- 2017-11-30 WO PCT/JP2017/042930 patent/WO2018101373A1/ja unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5295506B2 (ja) | 2006-02-21 | 2013-09-18 | 第一三共株式会社 | レボフロキサシン含有錠剤 |
US9149532B2 (en) | 2007-03-29 | 2015-10-06 | Daiichi Sanykyo Company, Limited | Pharmaceutical composition |
CN102058889A (zh) * | 2010-11-05 | 2011-05-18 | 王定豪 | 包含抗凝血类药物的分散片及其应用 |
WO2013022059A1 (ja) * | 2011-08-10 | 2013-02-14 | 第一三共株式会社 | ジアミン誘導体含有医薬組成物 |
US9402907B2 (en) | 2011-08-10 | 2016-08-02 | Daiichi Sankyo Company, Limited | Pharmaceutical composition containing diamine derivative |
WO2013161823A1 (ja) * | 2012-04-24 | 2013-10-31 | 第一三共株式会社 | 口腔内崩壊錠及びその製造方法 |
US20150110880A1 (en) | 2012-04-24 | 2015-04-23 | Daiichi Sankyo Company, Limited | Orally disintegrating tablet and production process therefor |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021017410A (ja) * | 2019-07-19 | 2021-02-15 | 日医工株式会社 | エドキサバン含有医薬組成物 |
JP7338857B2 (ja) | 2019-07-19 | 2023-09-05 | 日医工株式会社 | エドキサバン含有医薬組成物 |
WO2022024979A1 (ja) * | 2020-07-27 | 2022-02-03 | 第一三共株式会社 | ミロガバリンベシル酸塩を含有する口腔内崩壊錠 |
Also Published As
Publication number | Publication date |
---|---|
KR102631488B1 (ko) | 2024-01-30 |
CA3045418A1 (en) | 2018-06-07 |
EP3549585A4 (en) | 2020-07-29 |
EP3549585A1 (en) | 2019-10-09 |
CA3045418C (en) | 2021-10-19 |
JP7096164B2 (ja) | 2022-07-05 |
BR112019011169A2 (pt) | 2019-10-01 |
EP3549585B1 (en) | 2024-06-12 |
TWI812602B (zh) | 2023-08-21 |
TW201827049A (zh) | 2018-08-01 |
CN109996542A (zh) | 2019-07-09 |
JPWO2018101373A1 (ja) | 2019-10-24 |
KR20190089892A (ko) | 2019-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7028829B2 (ja) | 口腔内崩壊錠及びその製造方法 | |
JP7096164B2 (ja) | ジアミン誘導体を含む口腔内崩壊錠 | |
JP5296456B2 (ja) | 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠 | |
JP2015221826A (ja) | イルベサルタンとアムロジピンまたはその塩を含有する医薬組成物 | |
JP2017141299A (ja) | 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠 | |
JP5978335B2 (ja) | 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠 | |
JP7148319B2 (ja) | プラスグレルを含む口腔内崩壊錠 | |
JP2020196713A (ja) | エドキサバンを含有する口腔内崩壊錠 | |
JP6151413B2 (ja) | 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠 | |
JP5714652B2 (ja) | 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠 | |
JP7023186B2 (ja) | 認知症治療薬を含有する口腔内崩壊性錠剤 | |
WO2021132438A1 (ja) | ピロールカルボキサミドを含む口腔内崩壊錠 | |
JP2022072050A (ja) | エドキサバンを含有する口腔内崩壊錠 | |
CN115803020A (zh) | 含有苯磺酸米洛巴林的口腔崩解片剂 | |
JP6150564B2 (ja) | 口腔内速崩壊性錠剤 | |
JP2021113237A (ja) | 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠 | |
JP2018168185A (ja) | 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17875830 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2018554219 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3045418 Country of ref document: CA Ref document number: 20197015485 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112019011169 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2017875830 Country of ref document: EP Effective date: 20190701 |
|
ENP | Entry into the national phase |
Ref document number: 112019011169 Country of ref document: BR Kind code of ref document: A2 Effective date: 20190530 |